Positive results from pancreatic treatment trials boosted drug developer Immuneering's (IMRX.US) stock by 58% after hours.
On Thursday, drug developer Immuneering company (IMRX.US) reported positive data results for its candidate drug in a phase 2a trial, causing its stock price to surge 45%.
On Thursday, drug developer Immuneering (IMRX.US) reported positive data results from a phase 2a trial of its candidate drug IMM-1-104 in combination with modified gemcitabine/albumin-bound paclitaxel as a first-line treatment for pancreatic cancer. The company's stock price surged after hours, up 58% at the time of writing. According to a statement, the company reported that the first two out of five patients observed in the study achieved complete or partial responses, with an overall initial response rate of 40% and a disease control rate of 80%.
Immuneering stated that it expects to receive more data by the end of this year.
Related Articles
SITOY GROUP (01023) Announces Annual Results: Loss Attributable to Shareholders Narrows by 31.02% Year-on-Year to HK$123 Million
SITOY GROUP (01023) will distribute a special dividend of HK$0.02 per share on December 21.
CENTRAL NEW EGY (01735) proposes to change its name to "Central Smart Computing Technology Holdings Group Co., Ltd."
SITOY GROUP (01023) Announces Annual Results: Loss Attributable to Shareholders Narrows by 31.02% Year-on-Year to HK$123 Million
SITOY GROUP (01023) will distribute a special dividend of HK$0.02 per share on December 21.
CENTRAL NEW EGY (01735) proposes to change its name to "Central Smart Computing Technology Holdings Group Co., Ltd."
